Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer

NCT05172518 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

512

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms
Locally Advanced or Metastatic Breast Cancer

Interventions

DRUG: Taxane plus Intermittent Capecitabine
DRUG: Utidelone plus Intermittent Capecitabine
DRUG: Taxane plus Metronomic Capecitabine
DRUG: Utidelone plus Metronomic Capecitabine

Sponsor

Sun Yat-sen University

Collaborators

[object Object]